Investor Presentaiton
Leverage Unique Commercialization Capability to Capture
Rapid Growth in China Market
•
•
Diversified portfolio
该追利单抗注射液
贝优珠单抗注射液
阿木学抗注射液
Simina inction
Hovaizumab injectin
drix
ng
利妥昔单抗注射
4 commercialized products
23 assets in pipeline covering Oncology, Autoimmune, Ophthalmology, Metabolism
24%
Commercialization team
•
Expanded experienced sales and marketing team to ~1,600
employees
•
2020 world new cancer incidents: 19.3m
•
China new cancer incidents: 4.6m, 24%
(Vs US 2.3m, 12%)
Others
Cervix 22%
Lung
18%
uteri
2%
China new
Prostate
cancer
3%
Colorectum
12%
2020 world cancer moral cases: 10m
Pancreas
incidents
•
China cancer moral cases: 3m, 30% (Vs
US 0.6m, 6%)
3% Thyroid
5%
Oesophagus Liver
7%
9%
Stomach
Breast 10%
9%
Indication advantages
•
Competitiveness in large indications (NSCLC, HCC, GC, ESCC etc)
Advanced line treatments with excellent clinical data (e.g. 1L nsq/sq NSCLC,
•
1L HCC etc)
Note: Cancer data source IARC 2020 report
Innovent
Confidential
Copyright©2021 Innovent Biologics
Network coverage
Expanded coverage to about 4,000 hospitals and 900 DTP/pharmacies
across 300+ cities at the end of 2020
•
Early mover in market penetration to lower tier cities in 2020
8View entire presentation